The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Open accessAbstract
BRCA1-associated protein-1 (BAP1) mutations cause a new cancer syndrome, with a high rate of malignant mesothelioma (MM). Here, we tested the hypothesis that MM associated with germline BAP1 mutations has a better prognosis compared with sporadic MM. We compared survival among germline BAP1 mutation MM patients with that of all MM (N = 10 556) recorded in the United States Surveillance, Epidemiology, and End Results (SEER) data from 1973 to 2010. We identified 23 MM patients--11 alive--with germline BAP1 mutations and available data on survival. Ten patients had peritoneal MM, ten pleural MM and three MM in both locations. Thirteen patients had one or more malignancies in addition to MM. Actuarial median survival for the MM patients with germline BAP1 mutations was 5 years, as compared with <1 year for the median survival in the United States SEER MM group. Five-year survival was 47%, 95% confidence interval (24-67%), as compared with 6.7% (6.2-7.3%) in the control SEER group. Analysis of the pooled cohort of germline BAP1 mutation MM showed that patients with peritoneal MM (median survival of 10 years, P = 0.0571), or with a second malignancy in addition to MM (median survival of 10 years, P = 0.0716), survived for a longer time compared with patients who only had pleural MM, or MM patients without a second malignancy, respectively. In conclusion, we found that MM patients with germline BAP1 mutations have an overall 7-fold increased long-term survival, independently of sex and age. Appropriate genetic counseling and clinical management should be considered for MM patients who are also BAP1 mutation carriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Self-citationGermline mutations in BAP1 predispose to melanocytic tumors
Wiesner, T., Obenauf, A. C., Murali, R., Fried, I., Griewank, K. G., Ulz, P., Windpassinger, C., Wackernagel, W., Loy, S., Wolf, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.910 · Cited by 725
Yan, T. D., Deraco, M., Baratti, D., Kusamura, S., Elias, D., Glehen, O., Gilly, F. N., Levine, E. A., Shen, P., Mohamed, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9640 · Cited by 696
Carbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R., & Gaudino, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3459 · Cited by 590
Self-citationAbdel-Rahman, M. H., Pilarski, R., Cebulla, C. M., Massengill, J. B., Christopher, B. N., Boru, G., Hovland, P., & Davidorf, F. H. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100156 · Cited by 487
Kapur, P., Peña-Llopis, S., Christie, A., Zhrebker, L., Pavía-Jiménez, A., Rathmell, W. K., Xie, X.-J., & Brugarolas, J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70584-3 · Cited by 471
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008
Delgermaa, V., Takahashi, K., Park, E.-K., Le, G. V., Hara, T., & Sorahan, T. (2011) · Bulletin of the World Health Organization · doi:10.2471/blt.11.086678 · Cited by 405
Malignant mesothelioma: Facts, Myths, and Hypotheses
Carbone, M., Ly, B. H., Dodson, R. F., Pagano, I., Morris, P. T., Dogan, U. A., Gazdar, A. F., Pass, H. I., & Yang, H. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22724 · Cited by 376
Self-citationHakimi, A. A., Ostrovnaya, I., Reva, B., Schultz, N., Chen, Y.-B., Gonen, M., Liu, H., Takeda, S., Voss, M. H., Tickoo, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3886 · Cited by 357
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Carbone, M., Ferris, L. K., Baumann, F., Napolitano, A., Lum, C. A., Flores, E. G., Gaudino, G., Powers, A., Bryant-Greenwood, P., Krausz, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-179 · Cited by 323
Self-citationYan, T. D., Welch, L., Black, D., & Sugarbaker, P. H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl428 · Cited by 308
Germline BAP1 Mutations Predispose to Renal Cell Carcinomas
Popova, T., Hebert, L., Jacquemin, V., Gad, S., Caux-Moncoutier, V., Dubois-d’Enghien, C., Richaudeau, B., Renaudin, X., Sellers, J., Nicolas, A., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.012 · Cited by 279
A review of peritoneal mesothelioma at the Washington Cancer Institute
Sugarbaker, P. H., Welch, L. S., Mohamed, F., & Glehen, O. (2003) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(03)00045-0 · Cited by 270
The Worldwide Pandemic of Asbestos-Related Diseases
Stayner, L., Welch, L. S., & Lemen, R. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031811-124704 · Cited by 262
Njauw, C.-N. J., Kim, I., Piris, A., Gabree, M., Taylor, M., Lane, A. M., DeAngelis, M. M., Gragoudas, E., Duncan, L. M., & Tsao, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035295 · Cited by 254
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
Carbone, M., Emri, S., Dogan, A. U., Steele, I., Tuncer, M., Pass, H. I., & Baris, Y. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2068 · Cited by 253
Self-citation(1992) · PubMed · Cited by 252
Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005
Moolgavkar, S. H., Meza, R., & Turim, J. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9328-9 · Cited by 220
Germline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair
Ismail, I. H., Davidson, R., Gagné, J.-P., Xu, Z. Z., Poirier, G. G., & Hendzel, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3109 · Cited by 215
Malignant Pleural Mesothelioma: A Population-Based Study of Survival
Milano, M. T., & Zhang, H. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1cf2b · Cited by 212
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshikawa, Y., Sato, A., Tsujimura, T., Emi, M., Morinaga, T., Fukuoka, K., Yamada, S., Murakami, A., Kondo, N., Matsumoto, S., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02223.x · Cited by 179
A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Farley, M. N., Schmidt, L. S., Mester, J. L., Peña‐Llopis, S., Pavía-Jiménez, A., Christie, A. L., Vocke, C. D., Ricketts, C. J., Peterson, J. C., Middelton, L. A., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0111 · Cited by 167
Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
Henley, S. J., Larson, T. C., III, Wu, M., Antao, V. C., Lewis, M., Pinheiro, G. A., & Eheman, C. R. (2013) · International Journal of Occupational and Environmental Health · doi:10.1179/2049396712y.0000000016 · Cited by 164
Joseph, R. W., Kapur, P., Serie, D. J., Eckel‐Passow, J. E., Parasramka, M., Ho, T., Cheville, J. C., Frenkel, E., Rakheja, D., Brugarolas, J., et al. (2014) · Cancer · doi:10.1002/cncr.28521 · Cited by 161
Asbestos is not just asbestos: an unrecognised health hazard
Baumann, F., Ambrosi, J.-P., & Carbone, M. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70257-2 · Cited by 158
Self-citationGermline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144
A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma
Wadt, K., Choi, J., Chung, J., Kiilgaard, J. F., Heegaard, S., Drzewiecki, K. T., Trent, J. M., Hewitt, S. M., Hayward, N. K., Gerdes, A., et al. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12006 · Cited by 131
Pilarski, R., Cebulla, C. M., Massengill, J. B., Rai, K., Rich, T. A., Strong, L. C., McGillivray, B., Asrat, M., Davidorf, F. H., & Abdel‐Rahman, M. H. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22129 · Cited by 122
Germline BAP1 mutations predispose also to multiple basal cell carcinomas
de la Fouchardière, A., Cabaret, O., Savin, L. T., Combemale, P., Schvartz, H., Penet, C., Bonadona, V., Soufir, N., & Paillerets, B. B. (2014) · Clinical Genetics · doi:10.1111/cge.12472 · Cited by 115
Toward an Improved Definition of the Tumor Spectrum Associated With BAP1 Germline Mutations
Wiesner, T., Fried, I., Ulz, P., Stacher, E., Popper, H., Murali, R., Kutzner, H., Lax, S., Smolle-Jüttner, F., Geigl, J. B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2965 · Cited by 101
Zauderer, M. G., Bott, M. J., McMillan, R. R., Sima, C. S., Rusch, V. W., Krug, L. M., & Ladanyi, M. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829e7ef9 · Cited by 92
Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma
Cheung, M., Talarchek, J. N., Schindeler, K. L., Saraiva, E., Penney, L. S., Ludman, M. D., & Testa, J. R. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.05.018 · Cited by 88
Flores, R. M., Riedel, E., Donington, J. S., Alago, W., Ihekweazu, U. N., Krug, L. M., Rosenzweig, K. E., Adusumilli, P. S., Carbone, M., & Pass, H. I. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1903e · Cited by 81
Self-citationWomen With Malignant Pleural Mesothelioma Have a Threefold Better Survival Rate Than Men
Taioli, E., Wolf, A., Camacho‐Rivera, M., & Flores, R. M. (2014) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2014.04.040 · Cited by 80
Self-citationKapur, P., Christie, A. L., Raman, J. D., Then, M. T., Nuhn, P., Büchner, A., Bastian, P. J., Seitz, C., Shariat, S. F., Bensalah, K., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.09.041 · Cited by 77
Sex difference in diffuse malignant peritoneal mesothelioma
Yan, T. D., Popa, E., Brun, E. A., Cerruto, C. A., & Sugarbaker, P. H. (2006) · British journal of surgery · doi:10.1002/bjs.5377 · Cited by 71
Prevalence of germline BAP 1 mutation in a population‐based sample of uveal melanoma cases
Aoude, L. G., Vajdic, C. M., Kricker, A., Armstrong, B. K., & Hayward, N. K. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12046 · Cited by 67
The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma
Linton, A., Vardy, J. L., Clarke, S. J., & van Zandwijk, N. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.001 · Cited by 64
Hereditary uveal melanoma: A report of a germline mutation in BAP1
Höiom, V., Edsgärd, D., Helgadóttir, H., Eriksson, H., All‐Ericsson, C., Tuominen, R., Ivanova, I., Lundeberg, J., Emanuelsson, O., & Hansson, J. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22035 · Cited by 60
A BAP1 Mutation in a Danish Family Predisposes to Uveal Melanoma and Other Cancers
Aoude, L. G., Wadt, K., Bojesen, A., Crüger, D. G., Borg, Å., Trent, J. M., Brown, K. M., Gerdes, A., Jönsson, G. B., & Hayward, N. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072144 · Cited by 58
Ribeiro, C. S. M. F., Campelos, S., Moura, C. S., Machado, J. C., Justino, A., & Parente, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt135 · Cited by 53
Germline BAP1 mutations and tumor susceptibility
Goldstein, A. M. (2011) · Nature Genetics · doi:10.1038/ng.956 · Cited by 48
BAP1germline mutation in two first grade family members with uveal melanoma
Maerker, D., Zeschnigk, M., Schillinger, J., Lohmann, D. R., Worm, K., Bosserhoff, A., Krupar, R., & Jägle, H. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303814 · Cited by 26
Occupational exposure and regional variation of malignant mesothelioma in Norway, 1970–79
Mowé, G., & Gylseth, B. (1986) · American Journal of Industrial Medicine · doi:10.1002/ajim.4700090403 · Cited by 18
Mesothelioma: closer to the target?
Pass, H. I. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70139-6 · Cited by 6
Self-citation
Cited by
Husain, Colby, Ordóñez, Allen, Attanoos, Beasley, Butnor, Chirieac, Churg, Dacic, et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0124-ra · Cited by 619
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
Bononi, A., Giorgi, C., Patergnani, S., Larson, D., Verbruggen, K., Tanji, M., Pellegrini, L., Signorato, V., Olivetto, F., Pastorino, S., et al. (2017) · Nature · doi:10.1038/nature22798 · Cited by 401
Self-citationMesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Self-citationBiological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
Metadata
- Authors
- Baumann, F., Flores, E., Napolitano, A., Kanodia, S., Taioli, E., Pass, H., Yang, H., & Carbone, M.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11-07
- Volume
- 36
- Issue
- 1
- Pages
- 76-81
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2329699996
- Cited by
- 254
- References
- 46
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.